← Human Trials & Peer-Reviewed Studies

The effects of a thermogenic supplement on metabolic and hemodynamic variables and subjective mood states.

Plain-language guide to PMID 36862833 (2023): double-blind randomized controlled trial of Copper (Supplement).

Key Facts

PMID
36862833
Journal
Journal of the International Society of Sports Nutrition
Year
2023
Study type
Randomized Controlled Trial
Authors
Prather JM et al. (8 authors)
DOI
10.1080/15502783.2023.2185538

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

To determine whether a thermogenic supplement affects metabolic rate, hemodynamic responses, and mood states.

Who Took Part

PubMed tags the participants as women only.

Thereafter, subjects ingested the assigned treatment (active treatment containing caffeine, micronutrients, and phytochemicals [TR] or placebo [PL]).

Subjects repeated the same protocol with ingestion of the opposite treatment on a separate day.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some participants received a placebo instead of Copper (Supplement), giving a reference point.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

All variables were reassessed at 30-, 60-, 120-, and 180 min post-ingestion.

What Was Measured

Topics PubMed links to this paper include Caffeine, Fatty Acids, Nonesterified, Hemodynamics, Energy Metabolism and Fatigue.

Author keywords: Fat burners, Multi-ingredient, Supplements and Thermogenic supplement.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Journal of the International Society of Sports Nutrition), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.